ZANVASTRO Solution for injection Ref.[116918] Active ingredients: Zilganersen

Source: FDA, National Drug Code (US)  Revision Year: 2026 

1. Indications and Usage

ZANVASTRO is indicated for the treatment of Alexander disease in pediatric and adult patients.

2. Dosage and Administration

2.1 Recommended Dosage

Administer ZANVASTRO intrathecally after dilution using a lumbar puncture by, or under the direction of, healthcare professionals experienced in performing lumbar punctures.

The recommended dosage of ZANVASTRO is 50 mg intrathecally every 3 months.

The final dose volume of the intrathecal injection is determined by the patient's age [see Dilution and Preparation Instructions (2.2)].

Missed Dose(s)

If a dose of ZANVASTRO is missed, administer ZANVASTRO as soon as possible. Resume treatment at the recommended dosing frequency from the date of the most recently administered dose.

2.2 Dilution and Preparation Instructions

Read the entire Instructions for Use provided in the carton before diluting and preparing ZANVASTRO for intrathecal administration.

Each carton contains 1 vial of ZANVASTRO and 1 vial of diluent to be used together to prepare a single dose.

The diluent vial contains more volume than needed. Discard excess diluent prior to dilution as instructed below.

Prepare ZANVASTRO according to the instructions below and in Table 1.

Use aseptic technique when preparing and administering ZANVASTRO intrathecally.

1. Use a 3 mL and/or 10 mL syringe with an 18G to 22G needle to withdraw excess aCSF diluent from the diluent vial as determined by Table 1 based on the patient's age. Keep the diluent vial containing the remaining diluent for Step 3. Discard the syringe(s) containing the excess diluent.

2. Use a 3 mL syringe with an 18G to 22G needle to withdraw 2.8 mL of ZANVASTRO from the ZANVASTRO vial.

3. Add the withdrawn volume of ZANVASTRO to the diluent vial.

4. Gently invert the diluent vial (which now also contains ZANVASTRO) several times to mix the solution.

5. Attach an 18G or 19G filter needle (5 micron) to a 20 mL syringe. Withdraw the recommended dose volume of diluted ZANVASTRO from the diluent vial as determined by Table 1 based on the patient's age.

6. Remove the filter needle. Attach a syringe tip cap to the prepared dosing syringe.

7. Label the prepared dosing syringe per institution procedures prior to use or transport.

8. Discard any unused portion of the diluted solution and any unused contents of the ZANVASTRO vial.

Table 1. ZANVASTRO Dilution Procedure:

Patient AgeVolume of excess aCSF
diluent to withdraw from
the diluent vial and discard
Volume of ZANVASTRO to
add to the diluent vial
Volume of diluted
ZANVASTRO to withdraw
from the diluent vial for
administration
(dose volume)
Less than 2 years
old
12.6 mL2.8 mL10 mL
2 to 7 years
old (inclusive)
7.0 mL2.8 mL15 mL
8 years old and
above
1.4 mL2.8 mL20 mL

Storage of Prepared Dosing Syringe

ZANVASTRO contains no preservatives. Once drawn into the dosing syringe, the solution must be administered within:

  • 4 hours of preparation if kept at room temperature up to 30°C (86°F).
  • 24 hours of preparation if refrigerated at 2°C to 8°C (36°F to 46°F).

Do not freeze. Do not expose to heat. Protect the prepared dosing syringe from light as a precaution.

2.3 Administration Instructions

Procedural Preparation Instructions

  • If indicated by the clinical condition of the patient, consider sedation or local anesthesia.
  • If indicated by the clinical condition of the patient, consider imaging to guide intrathecal administration of ZANVASTRO.
  • Evaluate patients prior to intrathecal injection for factors that increase risks associated with lumbar puncture.

Administration

If the prepared dosing syringe is refrigerated prior to administration, allow the dosing syringe to warm to room temperature for at least 30 minutes prior to use for patient comfort. Do not use external heat sources to warm the dosing syringe [see Storage and Handling (16.2)].

Prior to administration, remove a volume of the patient's CSF approximately equal to the intended dose volume as appropriate for age, based on Table 2, using a lumbar puncture needle.

Table 2. Recommended Injection Dose Volume:

AgeInjection Dose Volume
After Dilution
Less than 2 years old10 mL
2 years old to 7 years old
(inclusive)
15 mL
8 years old and above20 mL

Administer ZANVASTRO as an intrathecal bolus injection over 1 to 3 minutes using the lumbar puncture needle. Do not flush the needle or any attached extension catheter, if used, after administration.

Discard the dosing syringe.

16.2. Storage and Handling

Store the ZANVASTRO vial and diluent vial in the refrigerator between 2°C and 8°C (36°F and 46°F) in the original carton to protect from light.

Once taken out of the refrigerator, the ZANVASTRO vial and diluent vial can be stored at room temperature up to 30°C (86°F) in the original carton for up to 14 days. If not used within the 14 days stored at room temperature, discard ZANVASTRO.

Do not freeze. Do not expose to heat. Protect from light as a precaution.

See Dosage and Administration (2.2) for instructions on how to store ZANVASTRO diluted solution.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.